Oncology Perspective

• Yes, Patients Are Getting More Complicated   It's not your imagination. Those problem lists are getting longer all the time, but the resources to deal with them are shrinking.
  Medscape, January 08, 2024
  49
• Experiencing the Evolution of Early NSCLC Treatment   Jared Weiss, MD, reflects on his first encounter in training with a patient with early NSCLC and how the treatment landscape has rapidly changed since then.
  Medscape, January 08, 2024
• Early NSCLC: Three Forms That Contribute to Failure to Diagnose   Jared Weiss, MD, reflects on the profound impact of patient experiences in which early diagnosis of NSCLC was missed.
  Medscape, January 08, 2024
• The Microbiome: It's What's Inside That Counts   The microbiome is the constellation of microscopic organisms that call the human body home, and its clinical implications are becoming increasingly clear to physicians.
  Medscape Gastroenterology, January 05, 2024
  3
• Healthcare Violence: Docs Bear Brunt of Business Pressures   Mark A. Lewis, MD, discusses violence in healthcare, including a recent experience with a patient.
  Medscape Oncology, January 05, 2024
  11
• Changes in the Treatment Landscape of Early-Stage Non-Small Cell Lung Cancer   Narjust Florez, MD, reflects on the significant changes in the treatment landscape of early-stage non-small cell lung cancer in recent years.
  Medscape, January 04, 2024
• Myelofibrosis Highlights From ASH 2023   Key studies on myelofibrosis, presented at ASH 2023, include the phase 3 MANIFEST-2 study, the phase 3 Transform-1 study, and multiple studies on treating anemia in myelofibrosis.
  Medscape, January 02, 2024
• Clinical Takeaways in Thrombocytopenia From ASH 2023   Clinical takeaways in immune thrombocytopenia (ITP) from ASH 2023 include efficacy of novel therapies, infection risk in chronic ITP, and ITP effects during pregnancy, as reported by Dr Howard Liebman.
  Medscape, January 02, 2024
• Triple Negative Breast Cancer e-Tumor Boards: Case 3: PD-L1 Negative TNBC with Homologous Recombination Deficiency   This case focuses on a patient with metastatic triple negative breast cancer which was initially HER2-positive.
  Medscape, January 02, 2024
• New Research Points to a Better Biomarker for MSI mCRC   David J. Kerr, CBE, MD, DSc, discusses the potential for identifying patients who are likely to be more responsive to immune checkpoint inhibitors.
  Medscape Oncology, January 02, 2024
• Key Abstracts in HER2-Positive Breast Cancer From SABCS 2023   Highlights in HER2+ breast cancer from SABCS 2023 include data from the HER2CLIMB-02 trial of tucatinib plus T-DM1 and a 9-year follow-up of the KATHERINE trial, as discussed by Dr Harold Burstein.
  Medscape, January 02, 2024
• Phase 1 Trials: Are We Using Optimal Drug Dose Schedules?   David J. Kerr, CBE, MD, DSc, discusses considerations for dosing schedules in Phase 1 trials.
  Medscape Oncology, December 28, 2023
  1
• Advances in Acute Lymphoblastic Leukemia From ASH 2023   Chemotherapy-free regimens in Philadelphia chromosome–positive acute lymphoblastic leukemia and optimization of combination therapies are among advances from ASH 2023 chosen by Dr Hagop Kantarjian.
  Medscape, December 28, 2023
• Highlights in HR-Positive Breast Cancer From SABCS 2023   Highlights in HR+/HER2- breast cancer from SABCS 2023 include the INAVO120 trial of novel PI3K inhibitor inavolisib and 3-year follow-up data from the NATALEE trial, as reported by Dr Harold Burstein.
  Medscape, December 27, 2023
• Are You Employing Genetic Testing Correctly for CRC?   The latest guidelines and data support wider use of germline testing for certain patients, says Dr David Johnson.
  Medscape Gastroenterology, December 27, 2023
  1
• The Clinical Implications of Findings From SABCS 2023   Dr Tarah J. Ballinger explores the impact of the INAVO120 study and the NATALEE trial on HR+/HER2- metastatic breast cancer.
  Medscape, December 27, 2023
• Chronic Lymphocytic Leukemia Highlights From ASH 2023   Doublet and triplet therapies as well as strong results from late-generation BTK inhibitors and sequencing are among CLL highlights from ASH 2023, as reported by Dr John Allan.
  Medscape, December 26, 2023
• Metastatic Breast Cancer Treatment: What the Future Holds Dr Eric Winer discusses the current state of metastatic breast cancer therapies and what the future holds, as clinicians strive to optimize patient care.
  Medscape Oncology, December 22, 2023
• Benign Ovarian Cysts: Will They Resolve Spontaneously?   Benign Ovarian Cysts: Will They Resolve Spontaneously?
  Medscape Ob/Gyn, December 21, 2023
  2
• Is It Possible to Predict the Risk for Pancreatic Cancer? A US-based team seeks to develop and validate a model allowing clinicians to predict the risk for pancreatic cancer.
  MDedge, December 21, 2023
  7
• Supercharge Your Medical Practice With ChatGPT An expert on artificial intelligence in oncology describes why, and how, to integrate ChatGPT into your clinical practice.
  Medscape Oncology, December 13, 2023
• ESMO 2022
  September 09, 2022
• BSH 2022
  April 20, 2022
• NCRI 2021
  November 12, 2021
• ESMO 2021
  September 30, 2021
• BSH 2021
  September 10, 2021
• BSH 2020
  August 15, 2021
• BTOG
  August 13, 2021
• ESMO 2020
  August 13, 2021